Consun Pharmaceutical Group Limited (1681.HK)
HKD 9.7
(-0.41%)
HKD 9.7
(-0.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.58 Billion CNY | 9.35% |
| 2022 | 1.45 Billion CNY | 0.1% |
| 2021 | 1.45 Billion CNY | 1.27% |
| 2020 | 1.43 Billion CNY | 2.31% |
| 2019 | 1.4 Billion CNY | 0.09% |
| 2018 | 1.4 Billion CNY | -7.15% |
| 2017 | 1.5 Billion CNY | 116.03% |
| 2016 | 698 Million CNY | 148.28% |
| 2015 | 281.13 Million CNY | 22.36% |
| 2014 | 229.75 Million CNY | 53.05% |
| 2013 | 150.11 Million CNY | -48.38% |
| 2012 | 290.82 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.49 Billion CNY | 0.0% |
| 2023 Q2 | 1.44 Billion CNY | 0.0% |
| 2023 Q4 | 1.58 Billion CNY | 0.0% |
| 2023 FY | 1.58 Billion CNY | 9.35% |
| 2022 FY | 1.45 Billion CNY | 0.1% |
| 2022 Q4 | 1.45 Billion CNY | 0.0% |
| 2022 Q2 | 1.29 Billion CNY | 0.0% |
| 2021 Q4 | 1.45 Billion CNY | 0.0% |
| 2021 FY | 1.45 Billion CNY | 1.27% |
| 2021 Q2 | 1.36 Billion CNY | 0.0% |
| 2020 Q4 | 1.43 Billion CNY | 0.0% |
| 2020 Q2 | 1.31 Billion CNY | 0.0% |
| 2020 FY | 1.43 Billion CNY | 2.31% |
| 2019 FY | 1.4 Billion CNY | 0.09% |
| 2019 Q2 | 1.61 Billion CNY | 0.0% |
| 2019 Q4 | 1.4 Billion CNY | 0.0% |
| 2018 Q4 | 1.4 Billion CNY | 0.0% |
| 2018 FY | 1.4 Billion CNY | -7.15% |
| 2018 Q2 | 1.34 Billion CNY | 0.0% |
| 2017 FY | 1.5 Billion CNY | 116.03% |
| 2017 Q2 | 1.36 Billion CNY | 0.0% |
| 2017 Q4 | 1.5 Billion CNY | 0.0% |
| 2016 Q4 | 698 Million CNY | 0.0% |
| 2016 FY | 698 Million CNY | 148.28% |
| 2016 Q2 | 263.99 Million CNY | 0.0% |
| 2015 Q2 | 216.44 Million CNY | 0.0% |
| 2015 Q4 | 281.13 Million CNY | 0.0% |
| 2015 FY | 281.13 Million CNY | 22.36% |
| 2014 Q2 | 184.86 Million CNY | 0.0% |
| 2014 FY | 229.75 Million CNY | 53.05% |
| 2014 Q4 | 229.75 Million CNY | 0.0% |
| 2013 Q4 | 150.11 Million CNY | 0.0% |
| 2013 Q2 | 259.57 Million CNY | 0.0% |
| 2013 FY | 150.11 Million CNY | -48.38% |
| 2012 FY | 290.82 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -1016.994% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 78.063% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -832.639% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -123.952% |
| Qianhai Health Holdings Limited | 94 Million HKD | -1590.672% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -70.878% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -75.848% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -138.85% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -130.447% |
| SSY Group Limited | 4.49 Billion HKD | 64.635% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -333.339% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -45.74% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.057% |